Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Type 2 Diabetes, Type 2 Diabetes Patient...
Phase NA
Enrollment 66
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the effects on diabetes self-management, health fatalism and metabolic parameters of individuals with type 2 diabetes. The study will be conducted in a health institution between February 2025 and May 2025 and participants will be assigned to experimental and control groups by simple random sampling method. The experimental group will be trained with motivational interviewing techniques based on the health belief model for 8 weeks, followed by sending reminder SMS for 4 weeks. The control group will receive no intervention. The study is expected to improve the self-care behaviors of individuals with diabetes by creating positive effects on diabetes management and health fatalism.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Experimental Group — individuals will receive diabetes education with motivational interviewing technique based on health belief model

Primary Outcomes

  • Type 2 DM Self-Management Scale (SMS) (three months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2025-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ataturk University
Contact Information
Study Contact:
Gülşen Altuntaş Çalım, PhD student
+905535383055
gulsenaltuntas13@hotmail.com
Cantürk Çapık, Prof. dr.
+90 442 231 2686
canturk@atauni.edu.tr
Gülşen Altuntaş Çalım
+905535383055
gulsenaltuntas13@hotmail.com
Manavgat and Aksu Family Health Center
Interventions
  • Other: Experimental Group — individuals will receive diabetes education with motivational interviewing technique based on health belief model
Study Locations (2 sites)
Manavgat and Aksu Family Health Center, Antalya, 07000 Turkey (Türkiye)
Manavgat and Aksu Family Health Center, Antalya, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Having type 2 diabetes for at least 6 months * To be over 18 years old * Have sufficient communication skills to answer verbal and written questions and fulfill instructions * Becoming literate * No physical, cognitive or mental impairment in answering the questions * Willingness to participate in research. Exclusion Criteria: * Under 18 years of age * Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process * The emergence of any health problem that prevents the person from continuing the research * Do not leave the study voluntarily.
Conditions Type 2 Diabetes, Subjective Cognitive De...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes (T2D) and dementia are both diseases with increasing incidence and prevalence globally, leading to substantial economic burdens for families and society. Notably, diabetes significantly increases the risk of cognitive dysfunction, which is classified into preclinical stage, mild cognitive impairment and dementia based on the disease severity. Cognitive dysfunction is a critical contributor to disability and mortality in elderly diabetes patients. Early diagnosis and intervention are crucial for delaying disease progression, enhancing treatment efficacy, and mitigating the impact of dementia. Currently, research and clinical management of cognitive dysfunction in individuals with diabetes are in their infancy, characterized by limitations such as single-center studies, limited sample sizes, inconsistent diagnostic criteria, and insufficient data sharing. Consequently, clinical diagnosis and treatment strategies are underdeveloped, medical staff's related knowledge is lacking, and potential therapeutic targets remain unexplored. In view of these problems and shortcomings, the population cohort study is supposed to be carried out based on accurate diagnosis and constructed the high standard information and sample bank. The study will establish the standard and quality system of T2D with cognitive dysfunction cohort study (unified standards and norms). The study will integrate the standard biological samples stratified acquisition function module (homogeneity and precision) of cognitive dysfunction in T2D, and complete the construction of biological samples bank and clinical diagnosis and treatment information database. The study will apply and develop brain structural and functional imaging technology to support precision diagnosis of cognitive dysfunction in T2D.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Naturalistic observation — Naturalistic observation

Primary Outcomes

  • Prevalence, incidence of cognitive dysfunction in type 2 diabetes (From 2016 to 2034)
  • Risk factors for cognitive dysfunction in type 2 diabetes, such as diabetes duration, poor glycemic control, hypertension, obesity, dyslipidemia, and active inflammation, et al. (From 2016 to 2034)
  • Biomarkers of cognitive dysfunction in type 2 diabetes (From 2016 to 2034)
  • Glycemic control targets for cognitive dysfunction in type 2 diabetes (From 2016 to 2034)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-10-01
Completion: 2034-10-01
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Principal Investigators:
  • Yan Bi, M.D., Ph.D. (STUDY_DIRECTOR) - Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Contact Information
Study Contact:
Yan Bi, M.D., Ph.D.
(86) 25-83105313
biyan@nju.edu.cn
Zhou Zhang, M.D., Ph.D.
(86) 25-83106666
zhangzhou@smail.nju.edu.cn
Yan Bi, M.D., Ph.D.
(86) 25-83105313
biyan@nju.edu.cn
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Interventions
  • Other: Naturalistic observation — Naturalistic observation
Study Locations (1 sites)
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008 China
Eligibility Criteria
Inclusion Criteria: * Age ≥45 years; * Type 2 diabetes diagnosed according to the American Diabetes Association criteria; * Willingness and ability to complete systematic neuropsychological tests; * Understanding of the research procedures and methods, potential benefits and risks of the trial, and sign written informed consent. Exclusion Criteria: * Fewer than 6 years of education; * Left-handedness; * Dementia; * Acute metabolic complications such as diabetic ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemic coma within the previous 3 months; * History or presence of neurological or psychiatric disorders; * Presence of hypothyroidism; * History of malignancy, or severe kidney or liver dysfunction.
Conditions Diabetic Kidney Disease, Type 2 Diabetes...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease. Although effective medications exist to slow the progression of kidney damage, they are often underused in primary care, particularly for individuals without a regular family doctor. In response to this gap, 46 community pharmacy-led primary care clinics were launched across Nova Scotia in 2023 to serve under-resourced areas. Pharmacists at these clinics can prescribe for many chronic conditions, but currently not for diabetic kidney disease. To address this, the research team collaborated with kidney, diabetes, and primary care experts, patient partners and regulatory bodies to develop and validate step-by-step prescribing guide (called algorithms) that support pharmacists in identifying and managing diabetic kidney disease. All medications included are approved, publicly funded in Nova Scotia, target people with earlier categories of diabetic kidney disease and includebuilt-in safety monitoring, nurse practitioner consultation or referral to a kidney doctor. This study will evaluate whether these algorithms improve kidney protective medication use which have shown to be beneficial for people with diabetes and kidney disease. The investigators will recruit 120 adults with type 2 diabetes from a provincial diabetes registry who do not have a primary care provider and screen them at pharmacy clinics for diabetic kidney disease. Those eligible and who wish to participate will be randomly assigned to either an intervention group receiving pharmacist-led care using the algorithms or a control group receiving usual care through walk-in, mobile, or virtual clinics. The investigators will measure how many patients begin and continue recommended medications, as well as any medication-related side effects or hospitalizations. Pharmacist participants will also complete a survey to identify what helps or hinders implementation in real-world practice. This research is relevant because it aims to expand access to kidney-protective treatments for people with diabetes, especially those with early forms of diabetic kidney disease who do not have regular access to primary care provider, ultimately improving long-term health outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Usual care for diabetic kidney disease management without primary care provider. — Participants in the control group will receive usual care for diabetic kidney disease which includes virtual care, walk-in clinics, or mobile health clinics for people without a primary care provider.
  • Other: Pharmacist-led validated diabetic kidney disease decision support algorithm. — Pharmacist working in community pharmacy primary care clinic in Nova Scotia will utilize previously validated diabetic kidney disease decision support algorithms for renin-angiotensin system inhibitors (RASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or nonsteroidal mineralocorticoid receptor antagonists (nsMRA).

Primary Outcomes

  • Effectiveness of Community Pharmacist-Led Prescribing Algorithms to Improve Guideline-Directed Medical Therapy Use in Diabetic Kidney Disease: The Rx4DKD Randomized Controlled Trial (From randomization to the end of follow-up period at 12 months.)
  • Effectiveness of Community Pharmacist-Led Prescribing Algorithms to Improve Guideline-Directed Medical Therapy Use in Diabetic Kidney Disease: The Rx4DKD Randomized Controlled Trial (From randomization to the end of the follow-up period at 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Scotia Health Authority
Contact Information
Study Contact:
Jo-Anne Wilson, BSc Pharm, ACPR, MEd, PharmD
9024886623
Jo-Anne.wilson@dal.ca
Laura Sills, RN, BSN
+1-(289)-201-4175
Laura.Sillis@nshelath.ca
Jo-Anne Wilson
9024886623
jo-anne.wilson@dal.ca
Dalhousie University
Interventions
  • Other: Usual care for diabetic kidney disease management without primary care provider. — Participants in the control group will receive usual care for diabetic kidney disease which includes virtual care, walk-in clinics, or mobile health clinics for people without a primary care provider.
  • Other: Pharmacist-led validated diabetic kidney disease decision support algorithm. — Pharmacist working in community pharmacy primary care clinic in Nova Scotia will utilize previously validated diabetic kidney disease decision support algorithms for renin-angiotensin system inhibitors (RASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or nonsteroidal mineralocorticoid receptor antagonists (nsMRA).
Study Locations (1 sites)
Dalhousie University, Halifax, Nova Scotia b3h 2y9 Canada
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol) * Adults who do not have primary care provider, * Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA Exclusion Criteria: * Hypotension * Type 1 diabetes * History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA). * Already receiving all three medications: RASi, SGLT2i, and nsMRA . * Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m² * Limited life expectancy of less than 1 year * Followed by a subspecialty physician (e.g., nephrologist or endocrinologist) * Unable to give consent
Conditions Obesity, Overweight
Phase PHASE3
Enrollment 1980
Locations 158 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Eloralintide — Administered SC
  • Drug: Placebo — Administered SC

Primary Outcomes

  • Percent Change from Baseline in Body Weight (Baseline, Week 64)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-06
Completion: 2030-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1980 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
205-331-4963
MFA Clinical Research
Interventions
  • Drug: Eloralintide — Administered SC
  • Drug: Placebo — Administered SC
Study Locations (158 sites)
MFA Clinical Research, Tuscaloosa, Alabama 35405 United States
Headlands Research - Scottsdale, Scottsdale, Arizona 85260 United States
Neighborhood Healthcare Institute of Health, Escondido, California 92025 United States
Ark Clinical Research - Fountain Valley, Fountain Valley, California 92708 United States
Desert Oasis Healthcare Medical Group, Palm Springs, California 92262 United States
Peninsula Research Associates, Rolling Hills Estates, California 90274 United States
Care Access - Sacramento, Sacramento, California 95831 United States
Southern California Clinical Research, Santa Ana, California 92701 United States
University Clinical Investigators, Inc., Tustin, California 92780 United States
Chase Medical Research, LLC, Waterbury, Connecticut 06708 United States
Eligibility Criteria
Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or * heart disease * Have a stable body weight (\<5% body weight change) for 90 days prior to screening. * Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes or type 2 diabetes * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Conditions Diabetes, Type 2 Diabetes
Phase PHASE2
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Umbilical cord mesenchymal stem cell injection expressing OCN19, while playing the role of MSCs, can directly stimulate the expression of insulin gene and the division and proliferation of islet beta cells, which is expected to further enhance the therapeutic effect of stem cells. In non-clinical studies, it was found that MSCs expressing OCN19 had better hypoglycemic effect than MSCs

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Biological: mesenchymal stem cells with OCN-19 — The patient received mesenchymal stem cells with OCN-19 three times
  • Biological: Mesenchymal stem cells — Ordinary mesenchymal stem cells were given
  • Biological: albumin injection — Placebo

Primary Outcomes

  • Daily insulin dose is used (From enrollment to 1 month, 3 months, 6 months and 1 year after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-06
Completion: 2029-12-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lu jin ,MD
Contact Information
Study Contact:
jin lu
021-18801784133
18801784133@163.com
jin lu
18801784133@163.com
Changhai Hospital
Interventions
  • Biological: mesenchymal stem cells with OCN-19 — The patient received mesenchymal stem cells with OCN-19 three times
  • Biological: Mesenchymal stem cells — Ordinary mesenchymal stem cells were given
  • Biological: albumin injection — Placebo
Study Locations (1 sites)
Changhai Hospital, Shanghai, China
Eligibility Criteria
1. Inclusion Criteria: 1. Accoding to WHO diagnostic standards, patients with type 2 diabetes (fasting blood glucose ≥ 7.0 mmol/L), 30-75 years old, regardless of gender; 2. Able to clearly understand the purpose of clinical trials and comply with trial requirements, willing to participate in this study, and sign an informed consent form; 3. 20kg/m2 ≤ Body Mass Index (BMI) ≤ 30 kg/m2; 4. 7.5% ≤ glycated hemoglobin ≤ 10%; 5. Insulin should be subcutaneously injected for more than six months, and insulin and/or other oral hypoglycemic drugs (limited to metformin only) should be used α The dosage of glycosidase inhibitors remained stable for the first 3 months before randomization; 6. During the study period, all males and females with reproductive potential were willing to accept the use of efficient contraceptive methods. 2. Exclusion Criteria: 1. 1 Type diabetes, pregnancy diabetes or other special type diabetes patients; 2. Patients with severe allergic constitution or allergic to any ingredients used in cell culture; 3. Patients who have used drugs that affect glucose metabolism within the past month, such as glucocorticoids, thiazide diuretics, oral contraceptives, tricyclic antidepressants, etc; 4. Screening the patients with acute complications such as diabetes ketoacidosis and non ketotic hyperosmolar syndrome in recent 6 months; 5. Serious cardiovascular and cerebrovascular events such as NYHA grade III or IV heart failure, myocardial infarction, cerebral infarction, and cerebral hemorrhage occurred within the past 6 months; 6. Patients with abnormal blood routine (including white blood cell or neutrophil count below the lower limit of normal, abnormal platelet count, and hemorrhagic disease); 7. Patients with liver and kidney dysfunction: such as serum bilirubin TBIL exceeding the upper limit of normal by 1.5 times, AST and ALT exceeding the upper limit of normal by 2.5 times, and serum creatinine exceeding 1.5 mg/dl for males and 1.4 mg/dl for females; 8. Patients with other serious systemic diseases (such as malignant tumors, central nervous system, cardiovascular system, blood system, digestive system, endocrine system, respiratory system, urogenital system, immune system, etc.); 9. Individuals who are currently using systemic hormones (such as glucocorticoids), immunosuppressants, or cytotoxic therapy; 10. Patients who received antibiotic treatment within the three months prior to study registration; 11. Patients who have received live or attenuated vaccines within 4 weeks prior to registration, or plan to receive live or attenuated vaccines during the study period; 12. Patients who are positive for HbsAg, Anti HCV, HIV or syphilis; 13. Patients with active infection (such as hepatitis B or hepatitis C, tuberculosis) requiring treatment; 14. Fever related diseases of unknown origin; 15. Disabled patients (blind, deaf, mute, intellectually disabled, physically disabled) and individuals with mental illnesses; 16. Patients who use drugs or have a history of adverse drug abuse and alcohol dependence within 5 years (with mental or substance abuse disorders that may interfere with the requirements of the trial); 17. Patients of childbearing age who are pregnant or lack effective contraceptive measures or have a pregnancy plan, as well as breastfeeding patients; 18. Patients who have received other stem cell treatments or participated in other clinical studies within the first three months of screening; 19. Patients who have not recovered due to adverse events (≥ level 2) caused by drug treatment within 4 weeks prior to the start of the study; 20. Patients with congenital or acquired immune dysfunction or a history of organ transplantation; 21. Patients with other serious diseases that may affect infusion results; 22. According to the judgment of the researchers, patients whose clinical conditions are not suitable for inclusion in this study.-

The Food for Health Study

NCT07254689
Recruiting
Conditions Type 2 Diabetes, Food Insecurity, Rural ...
Phase NA
Enrollment 43
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The project, called Food for Health (F4H), will study a new Produce Prescription Program (PPP) designed for rural Native American older adults. The study is based in the Confederated Salish and Kootenai Tribes (CSKT) of the Flathead Indian Reservation in Montana. In this community, many older adults face food insecurity and higher risk for Type 2 Diabetes (T2D). The tribal health department (THD) and local Food Resource Center (FRC) already provide important health and food support services, and this project builds on these strengths. Produce Prescription Programs (PPPs) is a type of nutrition support intervention that connects healthcare providers with local food programs to help patients access fresh, healthy foods. For example, an individual enrolled in the study will be "prescribe" fruits and vegetables in the form of a vouchers or coupons, which can be used to buy these foods at local food centers. Research shows that this type of program can reduce food insecurity, improve diet, and support better health. PPPs also fit well with tribal community priorities by supporting food sovereignty, culture-based nutrition education, and a stronger local food system. A key part of the study approach is using Community-Based Participatory Research (CBPR). CBPR means that community members, health providers, and researchers work together as equal partners. This way, the program is not just designed "for" the community, but "with" the community. The CSKT THD and community members have been involved in shaping this project from the start, and their priorities-like food security and food sovereignty-are at the center of the work. The investigators will carry out the study in two phases. Phase 1: Investigators will pilot test the acceptability of F4H in a small group of older adults (N=10) to understand the program's acceptability. The results will be used to refine and improve the program before moving to the next phase. Phase 2: Investigators will test the feasibility and impact of the refined F4H program with a larger group of older adults (N=33). Participant food insecurity and T2D risk factors, such as blood sugar and weight, will be measured before and after the program. Investigators expect that participants will have less food insecurity and healthier measures after completing the program. The clinic-to-community model is central to F4H. The THD will provide the prescriptions, and the FRC will be where participants redeem vouchers for fruits, vegetables, and other nutritious foods. The program will also include nutrition education that is grounded in Native culture and values. This model helps strengthen connections between healthcare and community services, creating a more supportive system for older adults. In addition to testing the program, investigators will study how it is carried out. This is called implementation research. It means paying attention to how the program fits into the community setting, what helps it succeed, and what…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Produce Prescription Program — Produce Prescription Programs (PPPs) are an upstream evidence-based intervention (EBI) to reduce food insecurity and improve health. PPPs connect healthcare services (via provider prescriptions) to vouchers for free healthy food at Food Resource Centers (FRC) to enhance access and promote healthy eating among patients. For this study the PPP will be referred to as The Food for Health (F4H) intervention and will use a clinic-to-community model to link a tribal health dept. (THD) to a local FRC through the development of new collaboration and programming. The clinic-to-community model builds local capacity for synergy across healthcare and community-based entities to address unmet health and social needs.

Primary Outcomes

  • Intervention Feasibility Measure (Time Frame: Pre (week 0), mid (week 8), post intervention (week 17))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-09-30
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 43 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Montana
Collaborators: National Institute of General Medical Sciences (NIGMS)
Contact Information
Study Contact:
Maja Pedersen, PhD
907-590-9694
maja.pedersen@mso.umt.edu
Taylor Steward Clinical Research Coordinator, MPH
9134065334
taylor.stewart@mso.umt.edu
Arlee Health Center
Interventions
  • Behavioral: Produce Prescription Program — Produce Prescription Programs (PPPs) are an upstream evidence-based intervention (EBI) to reduce food insecurity and improve health. PPPs connect healthcare services (via provider prescriptions) to vouchers for free healthy food at Food Resource Centers (FRC) to enhance access and promote healthy eating among patients. For this study the PPP will be referred to as The Food for Health (F4H) intervention and will use a clinic-to-community model to link a tribal health dept. (THD) to a local FRC through the development of new collaboration and programming. The clinic-to-community model builds local capacity for synergy across healthcare and community-based entities to address unmet health and social needs.
Study Locations (1 sites)
Arlee Health Center, Arlee, Montana 59821 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 55 years or older * Live on the Flathead Reservation * Self-identify as Native American (NA) * Food insecurity, as determined using Hunger Vital Sign™, a two question screener asked by providers. * Diabetes diagnosis * Pre-diabetic based on HbA1c lab results of (5.7-6.4%) or scores 5+ on the National Diabetes Prevention Programs screener based on health and history. Exclusion Criteria: * Individuals with end-stage renal disease * Their health provider states they should not participate
Conditions Asthma Bronchiale, Lung Function Tests, ...
Phase Not Applicable
Enrollment 260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • BHR and asthma balance (Baseline)
  • FeNO in study groups (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-06
Completion: 2027-12
Eligibility
Age: 7 Years and older
Sex: ALL
Volunteers: true
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helsinki University Central Hospital
Principal Investigators:
  • Mika Mäkelä, Professor, PhD, MD (STUDY_CHAIR) - HUS
Contact Information
Study Contact:
Janne Burman, PhD, MD
+358406517912
janne.burman@hus.fi
Anssi Koivuselkä, Nurse
anssi.koivuselka@hus.fi
Janne Burman, PhD, MD
+358406517912
janne.burman@hus.fi
HUS Skin and Allergy Hospital
Interventions
N/A
Study Locations (1 sites)
HUS Skin and Allergy Hospital, Helsinki, 00250 Finland
Eligibility Criteria
Inclusion Criteria: Healthy Controls * • Aged 7-15 years, both sexes * No diagnosis of asthma in childhood * No inhaled asthma medication during the previous 2 years * No wheezing or shortness of breath during the previous 2 years * Written informed consent from the participant and guardian Inclusion Criteria: Children with Asthma * Aged 7-15 years, both sexes * Physician-diagnosed asthma (ICD-10 codes J45.0/J45.1/J45.9) * Inhaled corticosteroid treatment for at least 6 months * Either: * Well-controlled asthma (c-ACT/ACT score ≥20) and no clinical need to intensify medication, or * Poorly controlled asthma with physician-confirmed need for intensified asthma medication Exclusion Criteria: * • Premature birth before 32 gestational weeks * Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma) * Severe underlying illness such as malignancy * Beta-blocker medication * Active immunological disease
Conditions Moderate to Severe Asthma
Phase PHASE2, PHASE3
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: CM310 — CM310 Recombinant Humanized Monoclonal Antibody Injection
  • Other: Placebo — Placebo

Primary Outcomes

  • Annualized rate of severe asthma exacerbations (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2023-04-28
Completion: 2032-05
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact Information
Study Contact:
Wang Wenjuan
010-63942533
wangwenjuan01@cspc.cn
Chen Wang
010-84205288
wangchen66366@163.com
China-Japan Friendship Hospital
Nan Su
010-84206185
sunan7632@163.com
China-Japan Friendship Hospital
Interventions
  • Drug: CM310 — CM310 Recombinant Humanized Monoclonal Antibody Injection
  • Other: Placebo — Placebo
Study Locations (1 sites)
China-Japan Friendship Hospital, Beijing, Beijin 100000 China
Eligibility Criteria
Inclusion Criteria: 1. Have the ability to understand the study and voluntarily sign the informed consent form. 2. Age ≥12 and ≤75 years old, male or female, weight ≥40 kg. 3. The subject has been diagnosed with asthma for at least 1 year, and the current disease status meets the diagnostic criteria of GINA 2022. 4. Pre-bronchodilator FEV1 measured ≤ 80% of the normal predicted value at screening and baseline visits (V1 and V2). 5. A positive bronchodilation test (≥12% increase in the FEV1 post-bronchodilator and an absolute FEV1 increase of ≥200 mL) within 24 months before consent or at screening. 6. The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent. 7. Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5 at screening and baseline visits (V1 and V2). 8. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before consent, and have not experienced a severe asthma exacerbation event within 1 month before consent, with at least one severe asthma exacerbation event occurring during treatment with medium-to-high dose ICS. 9. Subjects (including partners) have no plans to have children and voluntarily use highly effective contraception within 3 months after the last dose of study drug from the date of signing the informed consent. Exclusion Criteria: 1. Received biological agents with the same therapeutic purpose within 6 months before signing the informed consent. 2. Prior autoimmune disease or inflammatory treatment with biologic agents/systemic immunosuppressive agents within 8 weeks or 5 half- lives (whichever is longer) prior to informed consent. 3. Received immune globulin or blood products within 30 days before informed consent. 4. Subjects treated with systemic corticosteroids (except for topical, ophthalmic, or intranasal corticosteroids) from 4 weeks before signing the informed consent to the date of randomization. 5. Received live or attenuated vaccine within 3 months before informed consent signing or planned to receive live or attenuated vaccine during the study period. 6. Initiation of desensitization therapy within 3 months before informed consent. 7. Underwent bronchial thermoplasty within 12 months before informed consent. 8. Current smokers or former smokers who quit smoking less than 6 months or former smokers who quit smoking more than 6 months with a smoking history of more than 10 pack-years. 9. Chronic obstructive pulmonary disease (COPD) or other lung disease that may impair lung function, as judged by the investigator. 10. Active infection or acute infection requiring systemic anti-infective therapy from 4 weeks before enrollment to the time of randomization. 11. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection, even if the infection has resolved; Or the presence of unusual frequent, recurrent, or prolonged infections. 12. History of malignancy: subjects with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix are eligible to enter the study if they have completed curative treatment for at least 12 months before signing the informed consent. Subjects with other malignancies are allowed to enter the study if they have completed curative treatment for at least 5 years before signing the informed consent. 13. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator may affect the evaluation of the drug, including but not limited to: severe neurological disease, history of severe mental disorder, major cardiovascular disease, diabetes mellitus poorly controlled by intensive treatment, QTcF interval prolongation, or persistent arrhythmia. 14. Major surgery within 8 weeks prior to informed consent or planned surgery requiring general anesthesia or hospitalization for \> 1 day during the study period. 15. Fertile women with positive pregnancy test results during screening; Pregnant or lactating women. 16. Positive screening serologic test for HIV or treponema pallidum. 17. Chronic hepatitis B virus or hepatitis C virus infection. 18. Subjects with abnormal liver and kidney function, such as aspartate aminotransferase or alanine aminotransferase\>3 × ULN, or serum creatinine\>1.5 × ULN. 19. Have systemic diseases other than asthma that result in an elevated peripheral blood eosinophil count or other diseases such as helminth parasitic infections for which standard treatment is not received or does not respond. 20. Allergy or intolerance to components of CM310 injection or placebo or history of severe drug allergy or anaphylactic shock. 21. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent. 22. Subjects who have used heavy alcohol within 3 months before screening. 23. History of drug abuse within 5 years before signing informed consent. 24. The investigator considers that there are any conditions that may prevent the subject from completing the study or present a significant risk to the subject or other factors that may reduce the likelihood of enrollment.
Conditions Immune Deficiency, Immune Dysregulation ...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation. Patients determined by clinical history and outside evaluations to be of interest will be consented and enrolled into this study. Blood specimens, stored blood products and derivatives, saliva, hair, fingernail clippings, cord blood, umbilical cord, bone marrow, tissue biopsies and/or buccal swabs from such patients and/or their family members will be obtained for research studies related to understanding genetic and immunopathogenic bases of these diseases. Outside medical records may be obtained, and patient evaluations may be performed to correlate to research laboratory testing results.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Total number of underlying susceptibility trait(s) identified (Up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2010-07-16
Completion: 2027-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Principal Investigators:
  • Joshua D. Milner, MD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Joshua D. Milner, MD
212-305-2100
jdm2249@cumc.columbia
Yannett Franklin
212-305-0473
ym206@cumc.columbia.edu
Yannett Franklin
212-305-0473
ym206@cumc.columbia.edu
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
Interventions
N/A
Study Locations (1 sites)
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation, or mast cell homeostasis, or activation or immune dysregulation. * Blood relatives of enrolled subjects will be eligible for enrollment. * There will be no discrimination as to age, gender, race, or disability. * Subjects/guardians must be willing and able to give informed consent. * Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions. Exclusion Criteria: • The presence of an acquired abnormality of the immune system, such as cytotoxic chemotherapy or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.
Conditions Asthma
Phase Not Applicable
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The landscape of biologics therapy used in Hong Kong is currently unknown. The purpose of this study is to conduct a retrospective analysis of the use of biologics treatment for severe asthma in Hong Kong. The study aims to assess the landscape of biologics usage, evaluate the characteristics and conditions of patients before and after receiving biologic therapy, and provide insights into the effectiveness and safety of these treatments in the local population.

Design

Study type: Observational Observational model: Case Only Time perspective: Retrospective

Interventions / Regimen

  • Other: no interventions — No interventions, this is an observational study

Primary Outcomes

  • To determine the prevalence and patterns of biologics utilization for severe asthma in Hong Kong. (12 months)
  • To evaluate exacerbation rates before and after the initiation of biologic treatment. (12 months)
  • To evaluate the asthma control before and after the initiation of biologic treatment. (12 months)
  • To evaluate the lung function before and after the initiation of biologic treatment. (12 months)
  • To explore whether physicians are following international guidelines for the prescription of biologics (baseline)
  • To identify any adverse events associated with biologic therapy in the study population (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-26
Completion: 2027-12-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Fanny WS Ko, MD (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Fanny WS Ko, MD
852 35053133
fannyko@cuhk.edu.hk
David SC Hui, MD
852 35053133
dschui@cuhk.edu.hk
Fanny WS Ko, MD
852 35053133
fannyko@cuhk.edu.hk
Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK
Interventions
  • Other: no interventions — No interventions, this is an observational study
Study Locations (1 sites)
Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older. * Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines. * Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal) Exclusion Criteria: \- Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer

Microglia Activation in Asthma

NCT04307667
Recruiting
Conditions Asthma
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trail is to learn about how asthma influences brain function. The main questions it aims to answer are: * How airway inflammation in asthma affects the brain; and, * Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 6 visits, participants will: * Complete questionnaires * Complete computer tasks * Undergo allergy skin test * Undergo breathing tests including two whole lung allergen challenges * Give four blood samples * Complete brain imaging scans

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Biological: Whole lung antigen challenge (WLAC) — Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
  • Radiation: [18F]FEPPA — \[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.

Primary Outcomes

  • Presence of Neuroinflammation measured by TSPO observed via PET scan (up to 9 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-12-17
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Melissa Rosenkranz (PRINCIPAL_INVESTIGATOR) - Center for Healthy Minds
Contact Information
Study Contact:
Rachel Kaspari
608-263-0524
maia@medicine.wisc.edu
Danika Klaus
608-263-0524
maia@medicine.wisc.edu
Melissa Rosenkranz, PhD
University of Wisconsin Madison
Interventions
  • Biological: Whole lung antigen challenge (WLAC) — Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
  • Radiation: [18F]FEPPA — \[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
Study Locations (1 sites)
University of Wisconsin Madison, Madison, Wisconsin 53703-2637 United States
Eligibility Criteria
Inclusion Criteria: * Individuals with no health concerns that might affect the outcome of the study. * Age 18-75 years of age. * Physician diagnosis of asthma for at least six months prior to screening (can be determined at the discretion of an asthma/allergy physician member of the study team). Mild asthma will be defined as asthma that is well controlled with low-intensity treatment, e.g., SABA alone, as-needed low-dose ICS-LABA, or low-dose ICS plus as-needed SABA. * An increase in FEV1 \> 10% predicted after up to 8 puffs of albuterol OR positive methacholine defined as PD20 ≤ 400 mcg. (Historical data that is approved by the investigator is acceptable). * FEV1 ≥ 75% predicted at screening Visit 0a.FEV1 ≥ 70% predicted at baseline. * Positive immediate skin test for allergies to cat hair and reports asthma symptoms to cats, house dust mite and reports asthma symptoms to dust, or ragweed and reports asthma symptoms to ragweed (historical data documented within the last 5 years with our research group is acceptable). * Ability to tolerate a simulated MRI brain scanning session. * In the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements. * High-affinity TSPO-binding genotype. Mixed (high/low) binding-affinity genotype may be included at PIs discretion. Exclusion Criteria: * Current smoker (defined as more than 0.5 pack per week for the past 6 months and any smoking within two weeks of study procedures) or has a smoking history exceeding 5 pack years within the last 10 years * Currently receiving allergen immunotherapy * Use of psychotropic medication that might affect function of neurocircuitry implicated in the investigator's hypotheses at the discretion of the PI or Co-Investigator (Co-I) * Inability to hold medications detailed in the medication hold schedule * Needle phobia or claustrophobia * Major health problems such any of the following in the last 6 months: stroke/TIA, myocardial Infarction, stent placement, or acute coronary syndrome are definitively exclusionary. Decisions regarding other major health problems, such as autoimmune disease, history of carotid stenosis, heart disease, uncontrolled hypertension, lung diseases other than asthma, history of significant arrhythmias, etc. will be based upon the judgement of the PI/Co-I. * Use of biologic medication that might affect signaling pathways under investigation (at the discretion of the PI/Co-I) * Pre-existing chronic infectious disease * Scheduled use of non-selective beta-blockers prior to each study visit * Current use of beta-1 selective blockers (e.g., metoprolol, atenolol, acebutolol, betaxolol, esmolol, bisoprolo, and nebivolol) * Use of an investigational drug within 30 days of entering the study. This criterion will be reviewed on a case by case basis by the PI or Co-I to determine appropriate washout period. Appropriate wash out period may be greater than 30 days depending on the half-life of the investigational drug. Participants may be eligible for study participation after completing the washout period designated by the PI or Co-I (physician only). * Any MRI incompatibility as determined by most current MRI screening form * History of a diagnosed Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder * History of serious head trauma or seizure disorder (can be included at the discretion of the PI or Co-I) * Unable, in the judgement of the investigator, to comply with directions and/or tolerate the procedures required for participation in this study * Pregnant or breast-feeding or has a planned pregnancy during the course of the study * Have corrected vision and are not able to wear contacts or see sufficiently well to read without glasses or contacts, as glasses will not fit in the PET/MR head coil * Any other medical condition or disease that would impact subject safety or data integrity in the opinion of the PIs * Ever intubated due to asthma and has not had a severe exacerbation requiring an ER visit or hospitalization in the past year. * Participants with well-controlled asthma at enrollment using ICS for their asthma will undergo a supervised step-down of therapy. This step-down aligns with the 2020 Focused Updates to the Management of Asthma Guidelines: Clinician Guide. Participants who undergo the supervised step-down will be withdrawn unless their asthma remains well-controlled for at least 2 weeks prior to Visit 0a and at least 4 weeks prior to Visit 1 using PRN SABA only. Subjects will be monitored remotely during the supervised step-down. If the subject experiences any of the following during the supervised step-down, they will not be eligible to continue in the MAIA study: * Use of SABA \> 2 days a week for symptom relief (not for exercise-induced bronchoconstriction) * PEF \< 80% of baseline PEF for \> 2 days in a row * Use of systemic corticosteroids for asthma symptoms * ACQ greater than or equal to 1.5
Conditions Asthma
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Deep Phenotyping of adult asthma patients: * severity from mild to severe * both atopic and non-atopic * both childhood and adult onset * both smokers and non-smokers * corresponding pediatric cohort (Pediatric Arm of DZL All Age Asthma Cohort) with equivalent SOPs regarding collection of biomaterial and clinical data incl. lung function, further processing of biomaterial and further analyses

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Defining clinical asthma phenotypes by combining clinical, lung function and biomaterial data (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2014-03
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LungenClinic Grosshansdorf
Collaborators: German Center for Lung Research, Research Center Borstel
Principal Investigators:
  • Klaus F Rabe, MD PhD (PRINCIPAL_INVESTIGATOR) - LungenClinic Grosshansdorf, Grosshansdorf, Germany
  • Susanne Krauss-Etschmann, PhD (PRINCIPAL_INVESTIGATOR) - Research Center Borstel, Borstel, Germany
Contact Information
Study Contact:
Thomas J Bahmer, MD
+49 4102 601 2412
thomas.bahmer@uksh.de
Joern Bullwinkel, PhD
+49 4102 601 2410
j.bullwinkel@lungenclinic.de
Thomas J Bahmer, MD
+49-4102-601-2412
thomas.bahmer@uksh.de
LungenClinic Grosshansdorf
Interventions
N/A
Study Locations (1 sites)
LungenClinic Grosshansdorf, Großhansdorf, 22927 Germany
Eligibility Criteria
Inclusion Criteria: * Proven Diagnosis according to current GINA Guideline (2014) * Ability to read and understand German * Ability to understand and agree to informed consent Exclusion Criteria: * History of respiratory tract infection within the last 4 weeks before inclusion